Enrollment Guide 2021

Total Page:16

File Type:pdf, Size:1020Kb

Enrollment Guide 2021 Enrollment Guide 2021 Take advantage of all your Medicare Advantage plan has to offer. UnitedHealthcare Dual Complete® ONE (HMO D-SNP) H3113-005-000 Service area: New Jersey - Atlantic, Bergen, Burlington, Camden, Cumberland, Essex, Gloucester, Hudson, Hunterdon, Mercer, Middlesex, Monmouth, Morris, Ocean, Passaic, Salem, Somerset, Sussex, Union, Warren counties Plan Year: January 1, 2021 through December 31, 2021 Get more for your Medicare dollar. More choice and more guidance. Renew, our When it comes to Medicare, one size does not fit all. That’s why UnitedHealthcare® offers a broad range health and of Medicare products, so you have options to fit your wellness program. health care needs. UnitedHealthcare’s experienced advisors and licensed sales agents will guide you Renew can help by through choosing the plan that’s right for you. inspiring you to take charge of your health and wellness every day. Get the care you need when — It provides a wide variety and where — you need it. of useful resources and activities — including Whether it’s an appointment with your doctor brain games, healthy online, a call with a nurse at 3 a.m. or taking care recipes, learning of a wellness visit from the comfort of your home, courses, fitness activities, UnitedHealthcare makes it easier to connect you and more. All at no cost.1 with care so you can stay on top of your health — when, where, and how you need it. One-on-one help using your Medicare plan. At UnitedHealthcare®, it’s not just customer service. It’s 1-on-1 support to help answer your questions and take the extra steps to understand your needs. It’s helping navigate your care during a health event. And it’s helping you get the most out of your plan, so you can be at your best health. 1Renew by UnitedHealthcare is not available in all plans. Resources may vary. Y0066_INTRO_2021_C CSEX21DU4776506_000 Table of Contents Start with Medicare Basics......................................................................................... 4 Eligibility and Helpful Resources Plan Information Benefit Highlights................................................................................................ 8 Explore Your Additional Services.....................................................................11 My Additional Benefits...................................................................................... 12 Over-the-Counter (OTC) Benefit Renew Active™ Summary of Benefits.........................................................................................17 Plan Ratings.......................................................................................................44 Drug List Drug List.............................................................................................................48 Alternative Covered Drugs..............................................................................117 Ready to Enroll Plan Recap.......................................................................................................120 How to Enroll....................................................................................................122 Scope of Appointment Confirmation Form...................................................123 Enrollment Request Form...............................................................................125 Enrollment Receipt..........................................................................................143 Take Advantage of What’s Next.....................................................................144 Vendor Information..........................................................................................147 Questions? We're here to help. Call toll-free 1-844-560-4944, TTY 711 www.UHCCommunityPlan.com 8 a.m. - 8 p.m. local time, 7 days a week Y0066_EGTOC_2021_C UHEX21MP4713483_000 Start With Medicare Basics Review the basics to make sure this plan is a good fit Original Medicare is provided by the federal government and covers some of the costs of hospital stays (Part A) and doctor visits (Part B), but doesn’t cover everything. It does not include prescription drug coverage (Part D). Depending on your needs, you may want to add on more coverage. Original Medicare – Provided by the federal government Part A Part B Helps pay for hospital stays Helps pay for doctor visits and inpatient care and outpatient care Your options for more coverage: Option 1 OR Option 2 Add one or both of the following Choose a Medicare Advantage plan: to Original Medicare: Medicare Supplement Insurance Plan Medicare Advantage Plan Offered by private companies Offered by private companies Medicare Supplement Helps pay some of the out- Part C of-pocket costs that come Combines Part A (hospital with Original Medicare insurance) and Part B (medical insurance) in one plan Part D Medicare Part D Plan Usually includes prescription Offered by private companies drug coverage Part D May offer additional Helps pay for prescription benefits not provided by drugs Original Medicare Medicare Made ClearTM brought to you by UnitedHealthcare® 4 This is a Medicare Advantage Part C Health Maintenance Organization (HMO) plan Your plan is a Health Maintenance Organization (HMO) plan. That means you need to get healthcare services through a network of local doctors and hospitals. Here’s how your HMO plan works You will need to select a primary care provider (PCP). This health plan requires you to select a PCP from the network. Your PCP can oversee and help manage your care. You have coverage for emergency care. Emergency Services and Urgently Needed Services are covered no matter where you go. A network of providers for coordinated care The chart below shows what happens when you use network versus out-of-network resources with this plan. In-Network Out-of-Network Will the doctor or hospital Yes No accept my plan? Does this plan require a referral to see a Specialist or No No other providers? What will I pay for covered There is no copay or In most cases, you will have to services? coinsurance. pay the full cost for services. You can find a complete listing of network providers and facilities within your plan on our website. 5 Are you eligible for this plan? You are eligible for this plan if you’re enrolled in Medicare Parts A and B and receive full state Medicaid benefits (such as New Jersey Family Care A or Managed Long Term Services and Supports). Enrollment is available once per calendar quarter during the first three quarters of the year (January – September) based on your qualifying election type. What are the levels of eligibility in New Jersey? · Qualified Medicare Beneficiary Plus (QMB Plus) · Full Benefit Dual Eligible (FBDE) What are the income requirements for each eligibility level? Federal Poverty Income Social Security Income Level Level Resources not more than two QMB Plus At or lower than times Based on Medical Need status, institutionalized income levels, FBDE home/community based waivers Helpful Resources You may qualify for Extra Help Extra Help is a program for people with limited incomes who need help paying Part D premiums, deductibles and copays. To see if you qualify for Extra Help, call: · The Social Security Administration at 1-800-772-1213, TTY 1-800-325-0778 · Your state Medicaid office This information is not a complete description of benefits. Call 1-844-560-4944, TTY 711 for more information. Y0066_SWMB_2021_M H3113005000 UHNJ21HM4769854_000 6 Plan Information UHEX21MP4713485_000 7 Benefit Highlights UnitedHealthcare Dual Complete® ONE (HMO D-SNP) As a UnitedHealthcare Dual Complete® ONE (HMO D-SNP) member, you have no out-of-pocket expenses. You will not be responsible for any copayments or coinsurance for drugs or other covered services provided by plan providers. This is a short description of your 2021 plan benefits. For complete information, please refer to your Evidence of Coverage. Limitations, exclusions and restrictions may apply. Plan Costs Monthly plan premium $0 Medical Benefits Your Cost Doctor’s office visit Primary Care Provider: $0 copay Specialist: $0 copay (no referral needed) Virtual medical visits: $0 copay Preventive services $0 copay Inpatient hospital care $0 copay per stay (no limit on days) Skilled nursing facility (SNF) $0 copay per stay (no limit on days) Outpatient hospital, including surgery $0 copay Mental health (outpatient and virtual) Group therapy: $0 copay Individual therapy: $0 copay Virtual visits: $0 copay Diabetes monitoring supplies $0 copay for covered brands Diagnostic radiology services (such as $0 copay MRIs, CT scans) Diagnostic tests and procedures (non- $0 copay radiological) Lab services $0 copay Outpatient x-rays $0 copay Ambulance $0 copay for ground or air Emergency care $0 copay (worldwide) Urgently needed services $0 copay (worldwide) 8 Benefits and Services Beyond Original Medicare Your cost Acupuncture $0 copay Chiropractic Services $0 copay Plan Information Dental Services $0 copay Durable Medical Equipment (DME) $0 copay Family Planning Services and Supplies $0 copay Federally Qualified Health Centers $0 copay (FQHC) Fitness program through Renew Standard membership to participating fitness Active™ locations with access to group fitness classes – depending on availability. Programs such as, online brain exercises, activities and an in-person fitness orientation at no cost to you. For the complete details about the program, please visit www.UHCRenewActive.com, and click the link in the footer entitled Terms and Conditions. Hearing services — hearing exams and $0 copay hearing
Recommended publications
  • Camphor Revisited: Focus on Toxicity
    Camphor Revisited: Focus on Toxicity Committee on Drugs This commentary updates a previous AAP state- TABLE. List of Camphor-Containing Products ment developed by the Committee on Drugs con- Product % of Camphor cerning camphor.1 The original commentary re- Absorbine Arthritic Pain Lotion 10 flected the level of concern among pediatric Act-On Rub Lotion 1.5 practitioners and poison centers about the toxicity of Anabaim Lotion 3 camphor. Since the original statement, the Food and Aveeno Anti-Itch Conc. Lotion 0.3 t Drug Administration (FDA) has recognized camphor Avalgesic Banaig Muscle Pain Reliever 2 as a safe and effective topical antitussive, analgesic, Bangesic t anesthetic, and antipruritic agent.2 Following the ap- Ben Gay Children’s Vaporizing Rub 5 proval process in 1983, the FDA required that the Betuline Lotion t concentration of camphor in products not exceed Campho-phemque First Aid Gel 10.8 Campho-phenique Uquid 10.85 11%.2 Fligher concentrations were not more effective Campho-phemque Powder 4.375 and could cause more serious adverse reactions if Counterpain Rub t accidentally ingested. Most reported camphor-re- Deep Down Rub 0.5 lated fatalities involved agents containing a concen- Dencorub Cream Dermal Rub t tration greater than 11%. Dermolin Liniment t Ingestion of potentially toxic substances by chil- Emul-O-Balm 1.1 dren is related to the availabffity of a product in their Heet Lotion 3 3.6 environment. Camphor remains widely available Heat Spray Minit-Rub 3.5 (Table). The toxicity of camphor when inappropri- Mollifene Ear Drops t ately used is well documented.6 Ingestion is the Musterole Regular 4 most common route of potentially toxic exposure, Panalgesic 3 with rapid onset of toxic effects.
    [Show full text]
  • Absorbine Veterinary Liniment for Horses
    Doc# 03.287 Ver. 11 SAFETY DATA SHEET ABSORBINE® VETERINARY LINIMENT SECTION 1 - PRODUCT AND COMPANY IDENTIFICATION 1.1 Trade Name (as labeled): Absorbine® Veterinary Liniment Synonyms: N/A CAS No: Mixture 1.2 Product Use: Soothes sore muscles and stiff joints 1.3 Company Name: W.F. Young Company Address: 302 Benton Dr Company Address Cont: East Longmeadow, MA 01028 Business Phone: ( 413) 526-9999 Website: www.wfyoung.com 1.4 Emergency Telephone Number: (413) 526-9999 Date of Current Revision: January 17, 2017 Date of Last Revision: August 7, 2015 SECTION 2 - HAZARD IDENTIFICATION EMERGENCY OVERVIEW: This product is a green thin liquid with an acetone odor. Health Hazards: May cause skin, eye, and respiratory system irritation. Flammabilit Hazards: This product is a flammable liquid with a flash point over 20°F (-6. 7°C). Reactivit Hazards: None. Environmental Hazards: The environmental effectsof this product have not been investigated, however release may cause long term adverse environmental effects. US DOT Symbols: EU and GHS Symbols: Signal Word: Danger! 2.1 CLASSIFICATION OF SUBSTANCE OR MIXTURE IN ACCORDANCE WITH 29 CFR 1200 (OSHA HCSl AND THE EUROPEAN UNION DIRECTIVES: This product does meet the definition of a hazardous substance or preparation as defined by 29 CFR 1910. 1200 or the European Union Council Directives 67 /548/EEC, 1999/45/EC, 1272/2008/EC and subsequent Directives. EU HAZARD CLASSIFICATIONOF INGREDIENTS PER DIRECTIVE 1272/2008/EC: IndexNumber: EC# 201-939-0 This substance is not classified in the AnnexVI of Directive 67/548/EEC EC# 200-662-2 This substance is classified in the AnnexVI of Directive 67/548/EEC Index# 606-001-00-8 Substances not listed either individually or in group entries must be self classified.
    [Show full text]
  • Veterinary Dairy Spray Liniment by Dan Leiterman
    1-888-376-6777 www.crystalcreeknatural.com December 2011 Introducing - Veterinary Dairy Spray Liniment By Dan Leiterman Crystal Creek is pleased to announce the addition of the new Veterinary Dairy Spray Liniment Features: Veterinary Dairy Spray Liniment • Available In A 24 oz. Spray Bottle Or A One Gallon (128 oz.) Refill Jug (VDSL) to our family of liniments (Veterinary Dairy Liniment and • A High Performance – Strong Relief Formula: Lini-Rub). Veterinary Dairy Spray Liniment provides the same ‘Contrast Therapy’ Warming and Cooling excellent performance as the original Analgesic Pain Relief rub-on Veterinary Dairy Liniment, only now with the convenience of a Anti-Inflammatory spray-on application. Anti-Microbial Skin Support – an aloe vera based formula Veterinary Dairy Spray Liniment is a powerful analgesic that combines • New Color For Lingering Identification Of Sprayed Animals the proven benefits of both warming and cooling ‘contrast therapy’ for • Meets National Organic Program Standards – challenged muscle tissue and edema Consider For Organic Use relief. The deep penetrating warmth soothes and supports proper • Economical To Use: circulation, while the lingering Retail Price coolness helps to reduce edema and inflammation of muscle tissue. 24 oz. Spray Bottle $29.95 / bottle If you prefer a spray-on liniment, Case Price (6 bottles/case) try Veterinary Dairy Spray Liniment and see the difference – it is stronger $28.95 / bottle and is better priced than the One Gallon Jug competition. If you prefer rub-on $134.00 / gallon liniments, try the Veterinary Dairy Case Price (4 gallons/case) Liniment (a white cream based $128.00 / gallon liniment) or the Crystal Creek Lini- Rub (an oil based liniment) and experience their excellent performance.
    [Show full text]
  • In This Section
    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
    [Show full text]
  • Safety Data Sheet
    First issue: September 17, 2009 Revision date: October 27, 2014 SDS No. 007.636 Version: 5 SAFETY DATA SHEET In accordance with OSHA’s Hazard Communication Standard 29 CFR §1910.1200 SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1. Product identifier: Absorbine® Veterinary Liniment Gel 1.2. Relevant identified uses of the substance or mixture and uses advised against Topical Analgesic 1.3. Details of the supplier of the safety data sheet Manufacturer/Supplier: W. F. Young, Inc. 302 Benton Drive East Longmeadow, MA 01028 Telephone number for information: 413 526 9999 E-mail: [email protected] 1.4. Emergency telephone number 413 526 9999 SECTION 2: HAZARDS IDENTIFICATION 2.1. Classification of the mixture F, Xn, Xi R10, 22, 43 2.2. Label elements Flammable Keep out of the reach of children Harmful if swallowed May product an allergic reaction 2.3. Other hazards Inhalation of vapors can cause anesthetic effect. Page 1 of 8 First issue: September 17, 2009 Revision date: October 27, 2014 SDS No. 007.636 Version: 5 SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS 3.2. Mixtures Hazardous ingredients information Component CAS Nr. EINECS / Amount DSD DSD ELINCS (%) Hazard R-Phrases Symbol Ethanola,denatured 64-17-5 200-578-6 40 - 70 F R11 Menthol 89-78-1 201-939-0 4 Choroxylenol 88-04-0 201-793-8 0.5 Xi R43 Spearmint Oil 8008-79-5 Not classified 0.5-1.0 Xi R43 Propylene Glycola 57-55-6 200-338-0 1 - 5 Other Components: Remaining components of this alcoholic mixture are proprietary, non-hazardous and/or are present at concentrations below reportable limits.
    [Show full text]
  • Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000
    GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999.
    [Show full text]
  • First Quarter 2019
    Press release First quarter 2019 Issued: Wednesday, 1 May 2019, London U.K. GSK delivers sales of £7.7 billion +6% AER, +5% CER Total EPS 16.8p, +50% AER, +42% CER; Adjusted EPS 30.1p, +22% AER, +18% CER Financial highlights • Pharmaceuticals sales £4.2 billion, +4% AER, +2% CER; Vaccines £1.5 billion, +23% AER, +20% CER; Consumer Healthcare £2.0 billion, flat AER, +1% CER. • Total Group operating margin 18.6%. Adjusted Group operating margin 28.2%, +1.6 percentage points AER, +1.0 percentage point CER (Pharmaceuticals 29.8%; Vaccines 40.3%; Consumer Healthcare 21.7%). Benefits from strong sales growth and phasing of R&D. • Total EPS 16.8p, +50% AER, +42% CER. • Adjusted EPS 30.1p, +22% AER, +18% CER, driven by strong operating performance, continued financial efficiencies, reduction in minority share and a one-off benefit to associates. • Net cash flow from operations £663 million. Free cash flow £165 million. • 19p dividend declared for the quarter; continue to expect 80p for full year 2019. • 2019 Guidance reaffirmed. Product and pipeline highlights • Total HIV sales £1.1 billion, +7% AER, +4% CER, including Juluca sales of £70 million. - Dovato (dolutegravir+lamivudine), first once-daily 2-drug regimen for treatment-naive HIV patients, launched in US. - Long-acting cabotegravir+rilpivirine filed in the US for treatment of HIV. • Total new Respiratory product sales £631 million, +29% AER, +25% CER, including Trelegy £87 million; Nucala £152 million. • Shingrix sales £357 million driven by continued strong launch execution in US. • Continued
    [Show full text]
  • We Have Some Trouble with Special Characters and Displaying Monographs. 22.09.2018 ATC Code: D04AB01 Classification
    We have some trouble with special characters and displaying monographs. 22.09.2018 ATC code: D04AB01 Classification: PNP - Probably not porphyrinogenic Substance: Lidocaine Rationale for risk classification: Lidocaine is metabolized by CYP1A2, with only a minor contribution from CYP 3A4. Lidocaine is not listed as an inducer or as a mechanism-based inhibitor of CYP enzymes, nor is there any evidence of lidocaine capacity for Cyp-inhibition in clinical use. Lidocaine is reported as used uneventfully by 68 patients, and thus strong clinical evidence points to lidocaine as probably not porphyrinogenic. The systemic availability of lidocaine after restricted dermal use is usually low. Chemical description: Lidocaine hydrochloride is an amide derivative of diethyl amino acetic acid. Lidocaine has a lipophilic aromatic ring attached to a hydrophilic amino group by an amide linkage. Therapeutic characteristics: Lidocaine is a local anesthetic. In dermatological preparations lidocaine is used for the symptomatic relief of pain, itching or irritation of the skin or mucous membranes. It can be administered in topical formulations like ointment, gel or liniment for conditions like superficial skin wounds, insect bites, burns, herpes genitalis, and anal lesions or before various medical procedures. Extent of hepatic exposure: The plasma concentration of lidocaine is dependent on dose, administration method and vascularity of the site of administration. Whether the site of application has a traumatised or intact surface will also affect the absorption and systemic availability of the drug. Lidocaine is readily absorbed from mucous membranes and through damaged skin The hepatic exposure of lidocaine after restricted dermal use is probably not significant.. Systemic plasma concentrations after repeted anorectal administration of 5 % lidocaine ointment was found to be below uM (Zimmermann 2007).
    [Show full text]
  • Today's Research Tomorrow's Cure
    2018 Heart Research Institute Annual Review Accelerating Research Tomorrow’s cure Tomorrow’s Today’s research Today’s 2018 Heart Research Institute Annual Review Hello Future Accelerating 2018 Heart Research Institute Annual Review Research ACCELERATING Discoveries into therapies Knowledge into prevention Breakthroughs into cures Students into leaders Collaborations into partnerships 4 2018 Heart Research Institute Annual Review Inspiring Leaders 2018 Heart Research Institute Annual Review CONTENTS 06 HRI in 2018 08 Chairman’s Report 2018 10 Director of Cardiovascular Research Report 12 2018 Research and Media Highlights 16 Applied Materials Group 18 Atherosclerosis and Vascular Remodelling Group 20 Cardiac Imaging Group 22 Cardiometabolic Disease Group 24 Cardiovascular Medical Devices Group 26 Cell Therapeutics Group 28 Clinical Research Group 30 Haematology Research Group 32 Heart Rhythm and Stroke Prevention Group 34 High Blood Pressure Group 36 Thrombosis Group 38 Vascular Complications Group 40 Vascular Immunology Group 42 Inflammation and Fibrosis Research 44 PhD Students 45 Select Prizes and Awards 46 Select Conferences and Presentations 50 Select Publications 56 Board of Governors 59 International Board of Governors 60 Members of the Institute 62 Fundraising Report 66 Operations Report 6 2018 Heart Research Institute Annual Review The mission of the Heart Research Institute (HRI) is to prevent death and suffering from cardiovascular disease through an understanding of the biological processes that cause atherosclerosis and thrombosis, the major underlying causes of most heart attacks and strokes. 20 18 SHORT TERM LONG TERM The major short-term focus of our research There are four long-term objectives is to understand the development and for our research: progression of atherothrombotic conditions • To investigate mechanisms in which the arteries are narrowed and contributing to the pathogenesis restricted due to a build-up of fatty of cardiovascular disease.
    [Show full text]
  • Building Innovation, Performance and Trust
    Building Innovation, Performance and Trust Emma Walmsley, CEO Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements. Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate.
    [Show full text]
  • Dosage Form FDA Data Element Number
    Home Drugs Development & Approval Process (Drugs) Forms & Submission Requirements Electronic Submissions to CDER Data Standards Manual (monographs) Drugs Dosage Form FDA Data Element Number. None. CDER Data Element Number. C-DRG-00201 Data Element Name. Dosage Form. Data Element OID: 2.16.840.1.113883.3.26.1.1.2 Data Element NCI Concept ID: C42636 Version Number. 008 Description. This standard provides for all drug dosage forms. The granularity of data often requires that more specific dosage form terms be stored in automated databases than are represented in publications. These dosage form terms are available not only for use in databases that track approved drug products, but also for drug products such as: those that have not been approved, investigational drug products, homeopathic drug products, biologic products, veterinary drug products, and bulk drug products. A ‘use restrictions’ column is being added to help identify where a particular dosage form set or subset should be used (a=CDER Databases, b=NDC Directory, c=Orange Book). The definitions for Lotion, Cream, Ointment, and Paste were revised on June 21, 2006 to include information that would assist the user in differentiating between these dosage forms. These changes were the result of discussions during an FDA Advisory Committee with an open public forum, scientific studies that were published in refereed pharmaceutical journals, and internal discussions by Agency personnel, including the usual adherence to the criteria that are specified in MaPP 7600.4. A 1999 Food and Drug Administration Draft Guidance for Industry states: "A dosage form is the way of identifying the drug in its physical form.
    [Show full text]
  • Hinkson Creek Comprehensive Chemical Analysis Proposal
    UNITED STATES GOVERNMENT memorandum DATE: August 29, 2019 REPLY TO ATTN OF: David Alvarez, USGS, 573-441-2970, [email protected] SUBJECT: Cost estimate for the analysis of water and sediment samples from Hinkson Creek TO: Lynne Hooper, Boone County Resource Management, [email protected] Investigation of continued causes of impairment in Hinkson Creek is of interest to the Hinkson Creek Science Team. Some work has been done looking at basic water quality parameters, but little data exists looking at organic and inorganic contaminants which may be related to increased urbanization in the watershed. The Environmental Chemistry Branch was asked to develop a sampling plan which includes potential indicator chemicals that may indicate an increased contaminant loading into the Creek. Below is an estimate for the chemical analysis of water and sediment samples from Hinkson Creek. The costs below represent totals for the sampling at 5 sites each during an upcoming Fall and Spring season. Options for both water and sediment analyzes are included. Proposed chemicals to be investigated include: a suite of metals typical of urban environments, current use pesticides (CUP) related to agriculture, wastewater indicators (WI), polycyclic aromatic hydrocarbons (PAHs), organochlorine pesticides, polychlorinated biphenyls (total PCBs), and polybrominated diphenyl ether (PBDE) flame retardants. A tentative list of analytes is provided as an attachment to this memo. In addition to the specific chemical analyses, a screen for total estrogenicity of chemicals will be run using the in vitro yeast estrogen screen (YES). The YES assay is a cell-based assay where estrogens or estrogen-mimicking chemicals bind to an estrogen receptor which can be measured.
    [Show full text]